TY  - JOUR
T1  - The role of interleukin-6 gene in distinction of transudate-exudate in pleural effusions
TT  - Plevral efüzyonlarda transude ile eksuda ayrımında interlökin-6 geninin rolü
AU  - Önal, Müge Gülcihan
AU  - Akalın, Hilal
AU  - Akkuş, Armagan
AU  - Önal, Ömer
AU  - Dündar, Munis
PY  - 2024
DA  - June
Y2  - 2024
DO  - 10.17826/cumj.1441437
JF  - Cukurova Medical Journal
JO  - Cukurova Med J
PB  - Çukurova Üniversitesi
WT  - DergiPark
SN  - 2602-3032
SP  - 391
EP  - 399
VL  - 49
IS  - 2
LA  - en
AB  - Purpose: This study aims to appraise IL-6 gene expression in pleural fluid samples and establish a connection between expression levels and promoter polymorphisms for more accurate pleural effusion classification.Materials and Methods: A total of 38 adult patients (transudate (19) and exudate (19)) with pleural fluid and 33 healthy controls were included in the study. For the IL-6 gene expression study, RNA was isolated from transudate and exudate pleural fluids, and expression levels were compared between the two groups. Then, -174G>C (rs1800795), -572G>C (rs1800796) and, -597G>A (rs1800797) polymorphisms were analyzed using LightCycler® 480 II with real-time polymerase chain reaction from genomic DNA of controls and patients.Results: IL-6 levels were 7.13-fold more expressed in the exudate group than in the transudate group. No significant difference was found between the transudate-exudate groups in terms of polymorphisms. However, when we compared the transudate-exudate patient groups with the control groups, -174 G>C polymorphism and -597 G>A polymorphism were statistically significant. Conclusion: Pleural effusion treatment initiates with fluid characterization. In challenging cases, the current parameters are inadequate. Our findings indicate that IL-6 is a robust biomarker, independently distinguishing exudative and transudative states, surpassing traditional criteria. IL-6  shows promise for precise pleural effusion characterization, offering insights into pathophysiology and enabling targeted therapeutic interventions.
KW  - IL-6
KW  - mRNA Expression
KW  - Pleural Effusion
KW  - Genetic Polymorphism
N2  - Amaç: Bu çalışma, plevral sıvı örneklerinde IL-6 gen ekspresyonunu değerlendirmeyi ve ekspresyon düzeyleri ile promotör polimorfizmleri arasındaki ilişkiyi inceleyerek plevral efüzyon sınıflandırmasında daha doğru sonuçlar elde etmeyi amaçlamaktadır.Gereç ve Yöntem: Çalışmaya plevral sıvısı bulunan toplam 38 yetişkin hasta (19 transüda, 19 eksüda) ve 33 sağlıklı kontrol grubu dahil edildi. IL-6 gen ekspresyonu çalışması için, transüda ve eksüda plevral sıvılarından RNA izole edildi ve ekspresyon seviyeleri iki grup arasında karşılaştırıldı. Ardından, kontrol ve hasta gruplarının genomik DNA'larından LightCycler 480 II real-time polimeraz zincir reaksiyonu kullanılarak -174G>C (rs1800795), -572G>C (rs1800796) ve -597G>A (rs1800797) polimorfizmleri analiz edildi.Bulgular: Eksüda grubunda IL-6 düzeyleri, transüda grubuna göre 7,13 kat daha fazla ifade edildi. Transüda-eksüda grupları arasında polimorfizmler açısından anlamlı bir fark bulunamadı. Ancak transüda-eksüda hasta grupları kontrol grupları ile karşılaştırıldığında, -174G>C polimorfizmi ve -597G>A polimorfizmi istatistiksel olarak anlamlıydı.Sonuç: Plevral efüzyon tedavisi sıvı karakterizasyonu ile başlar. Zorlu vakalarda, mevcut parametreler yetersizdir. Bulgularımız, geleneksel kriterlerin ötesine geçerek eksüdatif ve transüdatif durumları bağımsız olarak ayırt eden güçlü bir biyobelirteç olarak IL-6 'yı işaret etmektedir. IL-6 , plevral efüzyonun hassas karakterizasyonu için umut vermekte olup, patofizyoloji hakkında bilgi sağlayarak hedeflenen tedavi yaklaşımlarına olanak tanımaktadır.
CR  - Zielinska-Krawczyk M, Krenke R, Grabczak EM, Light RW. Pleural manometry–historical background, rationale for use and methods of measurement. Respir Med. 2018;136:21-8.
CR  - Miserocchi G, Venturoli D, Negrini D, Del Fabbro M. Model of pleural fluid turnover. J Appl Physiol. 1993;75:1798-1806.
CR  - Porcel JM, Light RW. Pleural effusions. Dis Mon. 2013;59:29-57.
CR  - Maldonado F, Lentz RJ, Light RW. Diagnostic approach to pleural diseases: new tricks for an old trade. F1000Res. 2017;6:1135.
CR  - Krishna R, Rudrappa M. Pleural Effusion. Treasure Island, FL; StatPearls Publishing; 2018.
CR  - Feller-Kopman D, Light R. Pleural Disease N Engl J Med. 2018;378:740-51.
CR  - Rosse C, Gaddum-Rosse P. Hollinshead’s Textbook of Anatomy. Baltimore, Lippincott Williams & Wilkins.; 1997.
CR  - Tse HTK, Gossett DR, Moon YS, et al. Quantitative Diagnosis of Malignant Pleural Effusions by Single-Cell Mechanophenotyping. Sci Transl Med. 2013;5:212ra163.
CR  - HEFFNER JE. Diagnosis and management of malignant pleural effusions. Respirology. 2007;13:5-20.
CR  - Bouros D, Pneumatikos I, Tzouvelekis A. Pleural ınvolvement in systemic autoimmune disorders. Respiration. 2008;75:361-71.
CR  - Karkhanis VS, Joshi JM. Pleural effusion: diagnosis, treatment, and management. Emerg Med. 2012;4:31-52.
CR  - Porcel JM, Light RW. Diagnostic approach to pleural effusion in adults. Am Fam Physician. 2006;73:1211-20.
CR  - Antas P, Borchert J, Ponte C, Lima J, Georg I, Bastos M et al. Interleukin-6 and -27 as potential novel biomarkers for human pleural tuberculosis regardless of the immunological status. Microbes Infect. 2024;26:105238.
CR  - Kumar H, Kawai T, Akira S. Pathogen Recognition by the Innate Immune System. Int Rev Immunol. 2011;30:16-34.
CR  - Zamzam MA, Abd El-Aziz AA, El Wahsh RA, Sonbol AA, Abu El Nour SM. Role of interleukin-6 in diagnosis of pleural effusion. Egypt J Chest Dis Tuberc. 2016;65:173-7.
CR  - Shu CC, Wang JY, Hsu CL et al. Diagnostic role of inflammatory and anti-inflammatory cytokines and effector molecules of cytotoxic T lymphocytes in tuberculous pleural effusion. Respirology. 2015;20:147-54.
CR  - Yensey Ç, Aktoğu S, Kalenc S, Onur F. Proinflammatory cytokines: are they usefull in differential diagnosis of pleural effusions? Ege Tıp Dergisi. 2006;45:19-24.
CR  - Yalcin NG, Choong CKC, Eizenberg N. Anatomy and pathophysiology of the pleura and pleural space. Thorac Surg Clin. 2013;23:1-10.
CR  - Diaz-Guzman E, Dweik RA. Diagnosis and management of pleural effusions: a practical approach. Compr Ther. 2007;33:237-46.
CR  - Sertoğullarından B, Dallı A, Ekin S. How should approach to pleural effusion? J Chest Dis Crit Care Med. 2015;2:50-5.
CR  - Heffner JE, Brown LK, Barbieri CA. Diagnostic value of tests that discriminate between exudative and transudative pleural effusions. Primary Study Investigators. Chest. 1997;111:970-80.
CR  - Ferrari SL, Ahn-Luong L, Garnero P, Humphries SE, Greenspan SL. Two promoter polymorphisms regulating interleukin-6 gene expression are associated with circulating levels of c-reactive protein and markers of bone resorption in postmenopausal women. J Clin Endocrinol Metab. 2003;88:255-9.
CR  - Terry CF, Loukaci V, Green FR. Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation. J Biol Chem. 2000;275:18138-44.
CR  - Rivera-Chavez FA, Peters-Hybki DL, Barber RC, O’Keefe GE. Interleukin-6 promoter haplotypes and interleukin-6 cytokine responses. Shock. 2003;20:218-23.
CR  - Sharma A, Singh K, Biswas A, et al. Impact of interleukin 6 promoter polymorphisms (−174 G>C, −572 G >C and −597 G >A) on plasma IL-6  levels and their influence on the development of DVT: a study from India. Hematology. 2018;23:833-8.
CR  - Boeta-Lopez K, Duran J, Elizondo D, Gonzales E, Rentfro A, Schwarzbach AE et al. Association of interleukin-6 polymorphisms with obesity or metabolic traits in young Mexican-Americans. Obes Sci Pract. 2018;4:85-96.
CR  - Peng X, Shi J, Sun W, Ruan X, Guo Y, Zhao L et al. Genetic polymorphisms of IL-6  promoter in cancer susceptibility and prognosis: a meta-analysis. Oncotarget. 2018;9:12351-64.
UR  - https://doi.org/10.17826/cumj.1441437
L1  - https://dergipark.org.tr/tr/download/article-file/3747546
ER  -